[Federal Register Volume 67, Number 150 (Monday, August 5, 2002)]
[Notices]
[Pages 50652-50653]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-19712]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Applications Concerning Specific Inihibitors 
and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins

AGENCY: Department of the Army, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is 
made of the availability for licensing of the related U.S. patent 
applications concerning ``Specific Inhibitors and therapeutic Agents 
for Botulinum Toxin B and Tetanus Neurotoxins'' listed below. The 
United States Government, as represented by the Secretary of the Army, 
has rights in these inventions. Foreign rights are also available.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 1702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, bh at 
telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The following patents are available for 
licensing:
    (1) U.S. Patent Application No.: 09/570,022.
    Filed: May 12, 2000.
    Title: Previns as Specific Inhibitors and Therapeutic Agents for 
Botulinum
    Toxin B and Tetanus Neurotoxins.
    Supplementary Information: The compounds of the invention may be 
used as molecular building blocks to create compounds that are 
optimized for inhibiting the protease activity of Botulinum B and 
tetanus toxins. Foreign rights (PCT/US00/13215) are also available.
    (2) U.S. Patent Application No.: 09/570,023.
    Filed: May 12, 2000.

[[Page 50653]]

    Title: Buforin I as a Specific Inhibitor and Therapeutic Agent for 
Botulinum Toxin B and Tetanus Neurotoxins.
    Supplementary Information: The compounds of the invention may be 
used to inhibit the protease activity of Botulinum B and tetanus 
toxins. . Foreign rights (PCT/US00/12909) are also available.
    (3) U.S. Patent Application No.: 09/979,101.
    Filed: November 19, 2001.
    Title: Previns as Specific Inhibitors and Therapeutic Agents for 
Botulinum Toxin B and Tetanus Neurotoxins.
    Supplementary Information: The compounds of the invention may be 
used as molecular building blocks to create compounds that are 
optimized for inhibiting the protease activity of Botulinum B and 
tetanus toxins. Foreign rights (PCT/US00/13215) are also available.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-19712 Filed 8-2-02; 8:45 am]
BILLING CODE 3910-08-M